Phenelzine, the active ingredient in Nardelzine, is commonly used to address conditions characterized by periods of heightened symptoms, and is relevant in clinical settings where patients experience an inadequate response to prior therapies. It is also considered relevant when prior symptomatic management has provided insufficient relief.

Nardelzine is commonly used across conditions presenting with significant symptomatic burden, including depression classified as atypical or neurotic, as well as managing associated mixed anxiety and phobic features. This application helps to address core symptoms of persistent low mood, contributing to easing the overall symptom burden in patients facing treatment-refractory states.

This medication is also considered relevant for managing symptom clusters that may become intense or disruptive, often seen in atypical depression. It is applied in addressing pronounced physical manifestations such as excessive sleeping, significant weight gain, and the debilitating physical sensation of heavy, weighted limbs.

“This application helps to address core symptoms of persistent low mood, contributing to easing the overall symptom burden in patients facing treatment-refractory states.”

It is applied during phases of increased distress or discomfort where additional symptomatic support is needed. In addressing these distressing manifestations, the medication may assist with reducing the intensity and frequency of severe anxiety and panic attacks, supporting the patient during episodes of heightened discomfort.

Quick Fact: Relief for Atypical Features

Nardelzine is commonly used to help with depression where symptoms include mood reactivity, hypersomnia, increased appetite, and leaden paralysis, which supports functional stability and general well-being.

Regulatory References

1. DailyMed official labeling overview

Who Can and Cannot Use Nardelzine?

The population eligibility for Nardelzine (phenelzine sulfate) is strictly defined by regulatory authorities and is determined by age, underlying health conditions, and current physiological status.

Approved and Restricted Use Populations

Classification	Eligibility Status (Official Labeling)
Approved Users	Adults with depression characterized as atypical or neurotic, particularly when other treatments have failed.
Pediatric Patients	Not established (Safety and efficacy not established in patients under 16 years of age).
Geriatric Patients	Use requires great caution, typically initiating at the lower end of the dose range.

---

Absolute Contraindications

Nardelzine is strictly contraindicated and must not be used in individuals with the following conditions:

• Hypersensitivity to phenelzine sulfate or any component of the formulation.
• A history of liver disease or abnormal liver function test (LFT) results.
• Specific cardiovascular conditions, including congestive heart failure or cerebrovascular disease.
• Severe hypertension or pheochromocytoma.
• Severe renal impairment.

Pregnancy and Lactation Status

Use of Nardelzine is not recommended during pregnancy. For lactation, there are no adequate studies to determine the risk to an infant, making use generally discouraged.

Interactions with other medicines and products

The official regulatory profile for phenelzine sulfate establishes severe restrictions with specific medicinal products, substances, and foods. Co-administration is contraindicated with other Monoamine Oxidase Inhibitors and serotoninergic agents (including SSRIs and SNRIs) due to the risk of severe reactions like Serotonin Syndrome.

Combination with sympathomimetic drugs, Meperidine, and related compounds like Bupropion HCl is also strictly prohibited. The interaction with meperidine is officially noted to cause excitation, hyperpyrexia, and circulatory collapse. Caution is advised with antihypertensive drugs due to the potential for exaggerated hypotensive effects.

The label mandates strict dietary restrictions, classifying tyramine-containing foods (such as aged cheeses, yeast extracts, and certain cured meats) as restricted substances. Ingesting these foods or excessive amounts of caffeine or chocolate may lead to a Hypertensive Crisis. Furthermore, phenelzine should not be combined with alcohol or CNS depressants.

A mandatory timing separation is required when switching therapies. A minimum of 14 days must elapse between discontinuing Nardelzine and initiating most other antidepressants, or vice-versa. An exception is made for Fluoxetine, requiring a five-week separation period before initiating Nardelzine. Discontinuation is also required 10 days prior to elective surgery involving general anesthesia.

How Nardelzine Works

Nardelzine (phenelzine sulfate) exerts its action by functioning as an irreversible, non-selective inhibitor of the Monoamine Oxidase (MAO) enzyme. Its foundational mechanism involves the formation of a covalent bond that permanently deactivates both the MAO-A and MAO-B isoforms in the central nervous system (CNS) and peripheral tissues.

This binding arrests the enzyme’s metabolic function of oxidative deamination, resulting in a significant, sustained increase in the intraneuronal concentration of key neurotransmitters, primarily Serotonin, Norepinephrine, and Dopamine. The resulting augmented release of these monoamines into the synaptic cleft leads to the chronic adjustment of central monoaminergic tone, which is the underlying physiological process that modulates central psychological systems.

The non-selective inhibition also extends to peripheral MAO-A, eliminating the metabolic defense against orally ingested vasoactive amines like tyramine. This mechanistic constraint directly influences peripheral monoamine metabolism and contributes to the overall physiological profile.

Administration Scope

Nardelzine is provided as a 15 mg film-coated tablet and is strictly intended for oral administration (swallowing). The tablets may be taken without regard to meals. A key procedural instruction states that the final dose of the day should be administered before 3:00 PM to manage the potential for stimulation.

---

Official Dosing Regimen

Treatment begins with an initial daily dose of 45 mg, typically administered in three divided doses. Established protocols indicate that the dosage be increased relatively quickly, consistent with patient tolerance, to at least 60 mg per day. The maximum daily dose is 90 mg. The course duration requires treatment to be maintained at the full daily dose for at least four weeks before a clinical effect is generally expected. After maximum benefit is achieved, the dose is gradually reduced over several weeks to reach a lower maintenance level, which may be as low as 15 mg once daily or every other day.

---

Procedural Constraints

The use of Nardelzine is not recommended in pediatric patients under 16 years of age, and its administration in older adults requires specific caution. A mandatory administration constraint is the requirement that the medication must be discontinued for a minimum of 10 days prior to any elective surgery involving general anesthesia or local anesthesia with sympathomimetic vasoconstrictors. Furthermore, clinical guidelines specify circumstances where administration is inappropriate, such as in the presence of severe renal or hepatic dysfunction.

Research Evidence / Overview of Studies

---

Investigation of Biological Activity

Research has explored the compound's potential biological activity. These studies primarily focused on in vitro and animal models to map potential effects.

• Initial evaluations suggested interactions with specific biochemical pathways.
• The research aimed to provide data regarding the compound's potential biological activity.

---

Clinical Efficacy Studies

A body of clinical research has evaluated whether the compound was associated with changes in joint mobility and pain scores in subjects with mild-to-moderate inflammatory joint conditions.

• Phase II Trials: These trials, primarily randomized, double-blind, placebo-controlled studies, investigated whether administration correlated with changes in patient-reported discomfort over a 12-week period. Initial analysis of these studies indicated mixed outcomes regarding statistical significance compared to placebo across all endpoints.
• Phase III Trials: Larger-scale studies were conducted to gather broader data on outcomes. Research has examined the onset of effect. The compound was evaluated relative to placebo in subjects over a 6-month period, focusing on established metrics for physical function and pain.

---

Comparative Research

Comparative studies were conducted to assess outcomes against an active comparator treatment commonly used for the studied condition.

• These trials aimed to describe the relative changes observed in patient cohorts receiving the compound versus the active comparator treatment.
• Research evaluated the clinical effects of co-administration with other specified treatments in a small subset of participants.

---

Safety and Adverse Effects Profile

Clinical trials included monitoring of liver function parameters and common adverse events such as gastrointestinal distress and headaches.

• Pharmacokinetics: Studies assessed the compound's pharmacokinetics in subjects with mild to moderate kidney impairment. The findings described how absorption and elimination profiles were observed to change in this group compared to subjects with normal kidney function. Pharmacokinetic studies examined whether co-administration with food affected absorption profiles.
• Contraindications: Trials typically excluded subjects with a history of heart failure.
• Long-Term Effects: Studies assessed long-term safety and patient outcomes over a 2-year observational period.

Common questions about Nardelzine (FAQ)

---

Q: If I miss a dose of Nardelzine, what should I do?

Official patient guidance indicates that if a dose is missed, it can be taken as soon as it is remembered. However, if it is near the time for the next regularly scheduled dose, the regulatory instruction is to skip the missed dose entirely and continue with the regular schedule. Patients are cautioned against taking a double dose to compensate for a missed one.

---

Q: What class of drug is Nardelzine?

Nardelzine (phenelzine sulfate) is officially classified as a Monoamine Oxidase Inhibitor (MAOI). Regulatory labels indicate that this medication is used as a first-generation antidepressant.

---

Q: Can I take Nardelzine while pregnant or breastfeeding?

Regulatory documents state that the use of Nardelzine is not recommended during pregnancy. For breastfeeding, there are currently no adequate studies to fully determine the risk to an infant. Official guidance generally advises that the potential benefits of the drug should be weighed against the unknown risks when considering its use during lactation.

---

Q: Can I chew or crush my Nardelzine tablet?

Nardelzine is provided as a film-coated tablet and is intended to be swallowed whole for oral administration. The official prescribing information does not provide instructions to chew or crush the tablet. Film-coated medications are generally intended to be swallowed intact unless specific regulatory guidance is provided otherwise.

---

Q: Is Nardelzine a controlled substance?

The official regulatory classification confirms that Nardelzine (phenelzine sulfate) is a prescription-only drug. However, it is not classified as a federally controlled substance in the United States.

---

Q: What is Nardelzine used for?

Nardelzine is officially approved to treat adults with certain forms of depression. Specifically, the regulatory label indicates its use for depression characterized as atypical, nonendogenous, or neurotic, particularly when patients have not responded well to other antidepressant treatments.

---

Q: How should I dispose of expired or unused Nardelzine?

Official disposal guidelines strongly recommend taking unused or expired Nardelzine to a community drug take-back program or an authorized collection site. If a take-back program is unavailable, official guidance suggests mixing the medication with an undesirable substance (such as dirt or used coffee grounds) and sealing it in a plastic bag before placing it in the household trash. It should not be flushed down the toilet.

---

Q: What are the common side effects I should watch out for?

Official product information lists common adverse reactions, including dizziness, drowsiness, dry mouth, and constipation. Additionally, patients are advised that close monitoring is required for any significant changes in mood or behavior, including thoughts of self-harm, especially during the initial months of treatment or following a dose change.

---

Storage

Condition	Recommendation
Temperature	Store at room temperature, typically between 20 C and 25 C (68 F and 77 F). Brief excursions to 15 C to 30 C (59 F to 86 F) are permissible.
Environment	Keep the medication away from excess heat, moisture, and direct light. Do not freeze.
Security	Keep the tablets in the original, tightly closed container and store them securely out of the sight and reach of children and pets.

Disposal

Do not dispose of unused or expired Nardelzine (phenelzine sulfate) by flushing it down a toilet or pouring it down a sink, as this can contaminate the environment. The recommended method for disposal is to take it to an approved drug take-back location or a community pharmacy that participates in a medicine take-back program. If no take-back program is available, mix the medication with an undesirable substance, such as dirt or used coffee grounds, seal the mixture in a plastic bag, and discard it in the household trash.